Key Equity Analysts at Bernstein Have Maintained their ‘Market Perform’ rating for St James’s Place (LON:STJ) Shares Today. Their Price Target Provided Is GBX 1120


St James’s Place (LON:STJ) Rating Reaffirmed

The brokerage has just set a target price per share of GBX 1120 on St James’s Place (LON:STJ) shares. This is 17.28% from the stock price. In analysts note published on Monday, 14 December, Bernstein reconfirmed their Market Perform rating on shares of STJ.

From a total of 18 analysts covering St James’s Place PLC (LON:STJ) stock, 11 rate it a ”Buy”, 1 a “Sell”, and 7 a ”Hold”. This means that 58% of the ratings are positive. The highest target price is GBX 1197 while the lowest target price is GBX 785. The mean of all analyst targets is GBX 1033.22 with a 10.09% above today’s (GBX 952.5) stock price. St James’s Place PLC was the topic of 52 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Goldman Sachs maintained shares on December 10 with “Buy” rating. Numis Securities maintained shares with “Hold” rating and GBX 1015 target share price in a report from a November 27. RBC Capital Markets downgraded STJ stock in a recent report from December 10 to “Sector Perform” rating. JP Morgan maintained the rating on November 23. JP Morgan has a “Overweight” rating and a GBX 1024 price target on shares. Finally, Bernstein maintained the stock with “Market Perform” rating in a report issued on a December 7.

Approximately 199,851 shares of stock traded hands. St. James’s Place plc (LON:STJ) has risen 0.32% since May 15, 2015 and is uptrending. It has outperformed by 4.73% the S&P500.

Key Equity Analysts at Bernstein Have Maintained their ‘Market Perform’ rating for St James's Place (LON:STJ) Shares Today. Their Price Target Provided Is GBX 1120

The overall sentiment of institutions has increased to 1.36 in Q2 2015. Its up 0.53, from 0.83 in 2015Q2. The ratio increased, as 53 institutions have sold all the shares of St. James’s Place plc that they owned while 170 funds have taken shares off the table. 68 funds have purchased shares for the first time while 235 added to their positions. These institutions now hold 225.36 million shares or 4.37% less than the 235.67 million shares they owned in 2015Q2.

The Fund Perkins Capital Management Inc currently is holding shares equating to 6.69% of its total portfolio in St. James’s Place plc representing a total of 95,338 shares. Another fund,Conatus Capital Management Lp, is holding a total of 1.45 million shares equating to 5.79% of their holdings. Additionally, Endurant Capital Management Lp has a 245,526 share stake in St. James’s Place plc which represents 5.17% of their total portfolio. The Fund, Garland Capital Management Inc, based out of Washington, has also built up a stake in the stock, which represents a total of 4.21% of their total portfolio. Finally Sanders Capital Llc, a fund which is based in the state of New York reported a total holdings of 4.88 million shares.

Insider activity is a very important aspect to track on any stock. Going back to April 24, 2015, shareholders of St. James’s Place plc have witnessed 0 insider buys, and a total of 2 insider sales equating to a net activity of approximately $7.46 million . Murphy Mark W. sold 859 shares worth approximately $62,698. Starks Daniel J sold 100,000 shares worth approximately $7.39 million. Zellers Jason sold 396 shares worth approximately $28,924. Hill Barbara B sold 3,229 shares worth approximately $229,711. The company insider Fecho Jeff sold 5,174 shares worth $369,786.

St. James’s Place plc is a United Kingdom parent firm of the St. The company has a market cap of 4.98 billion GBP. James’s Place Wealth Management Group, which provides wealth management advice, investment management and related services to businesses and individuals across the United Kingdom. It has 28.35 P/E ratio. The Firm operates in four divisions: Life, Unit Trust, Distribution and Other.

According to Zacks Investment Research, “St. Jude Medical, Inc. is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.”